Kassi Filkins

Catch up on this week's highlights in retina.

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Catch up on this week's highlights in retina.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Catch up on this week's highlights in retina.

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.

Catch up on this week's highlights in retina.

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.

Catch up on this week's highlights in retina.

Ainnova has collaborated with leading pharmacies to offer free diabetic retinopathy screenings to patients with diabetes.

Catch up on this week's highlights in retina.

Catch up on this week's highlights in retina.

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of two tissue patches in immediate succession while minimizing damage to the surrounding tissue.

Focused on corneal disease research, Deng has been part of ARVO in various roles for more than 20 years.

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the upcoming Clinical Trials at the Summit 2025 meeting.

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.

SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.